



NEWS RELEASE

# Vesigen to Present at the 2023 Cell and Gene Meeting on the Mesa

10/5/2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that Paulash Mohsen, Chief Executive Officer, will present at the 2023 Cell and Gene Meeting on the Mesa on October 12 at 9:15 AM PT in Carlsbad, CA.

A livestream of the presentation will be available to registered attendees within the conference virtual platform.

## About Vesigen Therapeutics

Vesigen Therapeutics is a biotechnology company developing a novel, non-viral delivery technology for gene editing, RNA, and protein-based therapeutics. Vesigen's patented technology, called ARMMS (ARRDC1 Mediated Microvesicles), can be used to precisely deliver a wide range of payloads to a unique set of tissue and cell types. Vesigen has demonstrated highly efficient in vitro and in vivo functional delivery of a range of payloads across multiple cell types and is committed to developing transformative medicines that address current unmet medical needs. ARMMS were discovered and engineered into a drug delivery system at the Harvard T.H. Chan School of Public Health.

For additional information visit [www.vesigen.com](http://www.vesigen.com).

## Investors and Media:

Adam Bero, Ph.D.

Kendall Investor Relations

**abero@kendallir.com**

Source: Vesigen Therapeutics, Inc.